CIMA LABS Issued Fourth Patent for OraVescent(R)Oral Drug Delivery Technology.Business Editors & Medical/Health/Technology Writers MINNEAPOLIS--(BUSINESS WIRE)--Feb. 5, 2003 CIMA LABS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq:CIMA) today announced the issuance of a fourth patent (U.S. patent no. 6,509,036) from the U.S. Patent and Trademark Office covering its OraVescent technology. The most recent OraVescent patent applies to a drug delivery system based on an orally- administered dosage form A dosage form is the physical form of a dose of medication, such as a capsule or injection. The route of administration is dependent on the dosage form of a given drug. that releases a drug ingredient in a targeted area of the gastrointestinal (GI) tract. Absorption of the drug ingredient in the targeted area of the GI tract is optimized by the use of effervescence ef·fer·vesce intr.v. ef·fer·vesced, ef·fer·vesc·ing, ef·fer·vesc·es 1. To emit small bubbles of gas, as a carbonated or fermenting liquid. 2. To escape from a liquid as bubbles; bubble up. 3. . The Company believes this technology could be used for developing a targeted drug delivery Scientists began to study targeted drug delivery, because the traditional drug delivery system had many disadvantages, such as high toxic effect and high minimum effective dose. In traditional drug delivery system, after the patient takes some drugs, the drugs will be all over his body solution for a wider range of products that also may contain higher levels of drug ingredients. The first patent on CIMA's OraVescent technology, which was issued in March 2001, applies to a drug delivery system that utilizes a tablet placed under the tongue or between the gum and cheek to improve drug absorption across mucosal Mucosal Refers to tissues that produce mucus, such as the digestive, genital and urinary tracts. Mentioned in: Intestinal Polyps mucosal pertaining to or emanating from mucosa. membranes lining the mouth. The second and third OraVescent patents, which were issued in February and May of 2002, apply to dosage forms that are swallowed by the patient. These patents cover the composition of such dosage forms. About CIMA LABS CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(R). Based on our technologies, an active drug ingredient, which we frequently taste-mask, is formulated into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing chewing or mastication Up-and-down and side-to-side movements of the lower jaw, using the teeth to grind food for easier swallowing. During chewing, the tongue shapes food into a lump and saliva lubricates it for swallowing. or the need for water. CIMA's business involves a dual operating strategy. We develop and manufacture fast-dissolve versions of drugs for pharmaceutical company partners for whom we currently produce three branded prescription pharmaceuticals and three over-the-counter brands. CIMA is also developing proprietary products utilizing our fast-dissolve technologies, as well as our new OraVescent(R) enhanced absorption, transmucosal drug delivery system. CIMA's web site is www.cimalabs.com. Cautionary Statement This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. A number of factors could cause actual results to differ materially from CIMA's assumptions and expectations. Factors that may cause actual results to differ from CIMA's assumptions and expectations include those set forth under the heading "Factors That Could Affect Future Results" included in CIMA's most recent filings with the Securities and Exchange Commission. All forward-looking statements are qualified by, and should be considered in conjunction with, such cautionary statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion